GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, ...

GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission. Blenrep (belantamab mafodotin) becomes the first ...

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it failed a confirmatory ...

GSK plc GSK announced that the FDA has approved its supplemental new drug application (sNDA) seeking approval for its oral antibiotic Blujepa (gepotidacin) for treating uncomplicated urogenital ...

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus ...

Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collection targets using its ...

Harvey Jones has been hunting for the best shares to buy for his SIPP, and found what he thinks is one in a surprising place.

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...

When a Melbourne man first reconnected with his teenage crush online, he never imagined their story would lead to a fight for his life against an aggressive blood cancer.

(GLOBE NEWSWIRE) -- "Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there's no clear, consistent guidance -- ask five academic physicians and you'll get five different ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

GSK plc will present new data from its haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (6 - 9 December), reinforcing its potential to redefine ...